- Home
- PFSI vs RYTM Comparison
PFSI vs RYTM Comparison
Compare PFSI & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFSI
- RYTM
- Stock Information
- Founded
- PFSI 2008
- RYTM 2008
- Country
- PFSI United States
- RYTM United States
- Employees
- PFSI N/A
- RYTM N/A
- Industry
- PFSI Finance: Consumer Services
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- PFSI Finance
- RYTM Health Care
- Exchange
- PFSI Nasdaq
- RYTM Nasdaq
- Market Cap
- PFSI 6.4B
- RYTM 6.4B
- IPO Year
- PFSI 2013
- RYTM 2017
- Fundamental
- Price
- PFSI $118.32
- RYTM $97.86
- Analyst Decision
- PFSI Buy
- RYTM Strong Buy
- Analyst Count
- PFSI 7
- RYTM 13
- Target Price
- PFSI $122.57
- RYTM $109.77
- AVG Volume (30 Days)
- PFSI 391.1K
- RYTM 627.7K
- Earning Date
- PFSI 10-21-2025
- RYTM 11-04-2025
- Dividend Yield
- PFSI 1.02%
- RYTM N/A
- EPS Growth
- PFSI 97.42
- RYTM N/A
- EPS
- PFSI 7.22
- RYTM N/A
- Revenue
- PFSI $3,571,340,000.00
- RYTM $156,287,000.00
- Revenue This Year
- PFSI N/A
- RYTM $46.10
- Revenue Next Year
- PFSI $23.55
- RYTM $60.39
- P/E Ratio
- PFSI $16.23
- RYTM N/A
- Revenue Growth
- PFSI 65.89
- RYTM 53.55
- 52 Week Low
- PFSI $85.74
- RYTM $45.91
- 52 Week High
- PFSI $130.02
- RYTM $106.52
- Technical
- Relative Strength Index (RSI)
- PFSI 46.49
- RYTM 49.11
- Support Level
- PFSI $121.62
- RYTM $95.88
- Resistance Level
- PFSI $126.02
- RYTM $102.79
- Average True Range (ATR)
- PFSI 3.05
- RYTM 3.20
- MACD
- PFSI -1.16
- RYTM -0.25
- Stochastic Oscillator
- PFSI 13.59
- RYTM 32.99
About PFSI PennyMac Financial Services Inc.
PennyMac Financial Services Inc is a specialty financial services firm with a comprehensive mortgage platform and integrated business focused on the production and servicing of U.S. residential mortgage loans. The company operates through two segments: production and servicing. The production segment performs loan origination, acquisition and sale activities. The servicing segment performs loan servicing for newly originated loans.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.